RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed ex vivo in a process that involves de-differentiation and re-differentiation.
- Mechanism
- Curator reviewed
The hybrid TREG and Th2 phenotype of these cells inhibits the inflammatory pathways of COVID-19 through modulation of cytokines and chemokines and cross-regulation of Th1 and Th17 populations. This therapy also has been seen to mediate protection on lung alveolar tissue. The immunomodulation that occurs is in a T-cell receptor independent manner. Currently, RAPA-501-ALLO is being investigated against COVID-19.
- Code names
- RAPA-501-Allo
What you can answer from here — as of April 23, 2025
Which companies are running trials of RAPA-501-Allo, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account